Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06562270 · ClinicalTrials.gov registry record
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
A clinical trial of Alopecia Areata, sponsored by CorEvitas.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT06562270: Recruiting study of Alopecia Areata, sponsored by CorEvitas.
NCT06562270 is a study of Alopecia Areata that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 1,500 participants, below the 1,898-participant average among 26 other Alopecia Areata trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06562270, a study of Alopecia Areata, is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.
Primary Outcome
The major clinical outcomes include an assessment of the epidemiology of Alopecia Areata; to better understand the presentation, natural history, management and outcomes.
Conditions Studied
Study Locations (1)
Massachusetts
- CorEvitas, LLC - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2024-03-07 |
| Est. Completion | 2099-12-31 |
What NCT06562270 shows while recruiting
NCT06562270 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 1,898-participant average among 26 other Alopecia Areata trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 0 interventions.
NCT06562270 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06562270 about?
NCT06562270 is a clinical study titled "CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry". Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to pat...
What is the current status of trial NCT06562270?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2024-03-07. Estimated completion is 2099-12-31.
What conditions does trial NCT06562270 study?
This clinical trial studies the following conditions: Alopecia Areata.
Who is sponsoring clinical trial NCT06562270?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06562270 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06562270's enrollment target sits among peer trials
1,500 5th of 26 higher than 21 of 26 other Alopecia Areata trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Intralesional Cyclosporine for Alopecia Areata
RECRUITING · Early Phase 1
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI